Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Surpassing 1,000 Company Owned Company Operated stores
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Subscribe To Our Newsletter & Stay Updated